A145020 Stock Overview
Develops and manufactures biopharmaceuticals in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A145020 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Hugel, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩276,000.00 |
| 52 Week High | ₩326,000.00 |
| 52 Week Low | ₩139,500.00 |
| Beta | 0.59 |
| 1 Month Change | 0.91% |
| 3 Month Change | 2.99% |
| 1 Year Change | 92.33% |
| 3 Year Change | 80.27% |
| 5 Year Change | 118.53% |
| Change since IPO | 391.98% |
Recent News & Updates
Hugel, Inc.'s (KOSDAQ:145020) Intrinsic Value Is Potentially 94% Above Its Share Price
Dec 15
Hugel (KOSDAQ:145020) Has A Rock Solid Balance Sheet
Oct 19Recent updates
Hugel, Inc.'s (KOSDAQ:145020) Intrinsic Value Is Potentially 94% Above Its Share Price
Dec 15Hugel (KOSDAQ:145020) Has A Rock Solid Balance Sheet
Oct 19An Intrinsic Calculation For Hugel, Inc. (KOSDAQ:145020) Suggests It's 39% Undervalued
Sep 13There's Reason For Concern Over Hugel, Inc.'s (KOSDAQ:145020) Price
Aug 09Estimating The Intrinsic Value Of Hugel, Inc. (KOSDAQ:145020)
Jun 10Hugel (KOSDAQ:145020) Seems To Use Debt Rather Sparingly
Apr 19Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest
Mar 29Hugel, Inc.'s (KOSDAQ:145020) 25% Price Boost Is Out Of Tune With Earnings
Mar 05Calculating The Fair Value Of Hugel, Inc. (KOSDAQ:145020)
Mar 04Are Hugel, Inc.'s (KOSDAQ:145020) Mixed Financials Driving The Negative Sentiment?
Mar 19What Is The Ownership Structure Like For Hugel, Inc. (KOSDAQ:145020)?
Feb 25Does Hugel (KOSDAQ:145020) Have A Healthy Balance Sheet?
Feb 04
The Hugel (KOSDAQ:145020) Share Price Has Gained 197%, So Why Not Pay It Some Attention?
Jan 17Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?
Dec 29Does This Valuation Of Hugel, Inc. (KOSDAQ:145020) Imply Investors Are Overpaying?
Dec 14How Many Hugel, Inc. (KOSDAQ:145020) Shares Do Institutions Own?
Nov 24Shareholder Returns
| A145020 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -0.9% | 4.6% | 1.9% |
| 1Y | 92.3% | 22.4% | -7.7% |
Return vs Industry: A145020 exceeded the KR Biotechs industry which returned 22.4% over the past year.
Return vs Market: A145020 exceeded the KR Market which returned -7.7% over the past year.
Price Volatility
| A145020 volatility | |
|---|---|
| A145020 Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.6% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A145020 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A145020's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 594 | Ji-hoon Sohn | www.hugel.co.kr |
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name.
Hugel, Inc. Fundamentals Summary
| A145020 fundamental statistics | |
|---|---|
| Market cap | ₩3.04t |
| Earnings (TTM) | ₩112.04b |
| Revenue (TTM) | ₩363.79b |
27.1x
P/E Ratio8.4x
P/S RatioIs A145020 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A145020 income statement (TTM) | |
|---|---|
| Revenue | ₩363.79b |
| Cost of Revenue | ₩85.33b |
| Gross Profit | ₩278.45b |
| Other Expenses | ₩166.41b |
| Earnings | ₩112.04b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.17k |
| Gross Margin | 76.54% |
| Net Profit Margin | 30.80% |
| Debt/Equity Ratio | 2.8% |
How did A145020 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 19:04 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hugel, Inc. is covered by 26 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyeryeong Kim | CGS International |
| Seohyun Lee | Citigroup Inc |
| Hyonseok Kim | CLSA |